Dermatology
| Atopic Dermatitis
Dermatology
Atopic Dermatitis
68-week safety results of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis from STREAM-AD Phase 2b dose-ranging and withdrawal study
book_2
Source:
EADV 2024 - Oral session
calendar_today
Published on Medfyle:
October 2024
import_contacts
5
min
In this medfyle
Amlitelimab is an anti-OX40L in development for AD. Phase 2b results presented at EADV 2024 demonstrate an acceptable safety profile, but ongoing trials will provide additional data.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2024 Infomedica-Medfyle. All rights reserved.
Source: 68-week safety results of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis from STREAM-AD Phase 2b dose-ranging and withdrawal study. Weidinger S, et al. Presented at EADV 2024; FC08.01; Abstract #3310.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
